
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3674666/publications.pdf Version: 2024-02-01



ΙΛΥ Δ ΕΙςημαλι

#	Article	IF	CITATIONS
1	Infection in Solid-Organ Transplant Recipients. New England Journal of Medicine, 2007, 357, 2601-2614.	13.9	1,660
2	Marked prolongation of porcine renal xenograft survival in baboons through the use of α1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nature Medicine, 2005, 11, 32-34.	15.2	560
3	Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science, 2015, 350, 1101-1104.	6.0	511
4	Cytomegalovirus in transplantation ? challenging the status quo. Clinical Transplantation, 2007, 21, 149-158.	0.8	245
5	Identification of a Full-Length cDNA for an Endogenous Retrovirus of Miniature Swine. Journal of Virology, 1998, 72, 4503-4507.	1.5	231
6	Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients. Clinical Microbiology Reviews, 2004, 17, 770-782.	5.7	229
7	The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. European Respiratory Journal, 2012, 40, 990-1013.	3.1	211
8	Xenotransplantation: Infectious Risk Revisited. American Journal of Transplantation, 2004, 4, 1383-1390.	2.6	176
9	<i>Pneumocystis jiroveci</i> in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13587.	0.8	159
10	Infection in Organ Transplantation: Risk Factors and Evolving Patterns of Infection. Infectious Disease Clinics of North America, 2010, 24, 273-283.	1.9	144
11	Transmission of Infection With Human Allografts: Essential Considerations in Donor Screening. Clinical Infectious Diseases, 2012, 55, 720-727.	2.9	136
12	Current status of xenotransplantation and prospects for clinical application. Xenotransplantation, 2009, 16, 263-280.	1.6	126
13	Identification of Exogenous Forms of Human-Tropic Porcine Endogenous Retrovirus in Miniature Swine. Journal of Virology, 2004, 78, 2494-2501.	1.5	120
14	Activation of Cytomegalovirus in Pig-to-Primate Organ Xenotransplantation. Journal of Virology, 2002, 76, 4734-4740.	1.5	116
15	Infections in immunocompromised hosts and organ transplant recipients: Essentials. Liver Transplantation, 2011, 17, S34-S37.	1.3	116
16	Xenotransplantationâ€essociated infectious risk: a WHO consultation. Xenotransplantation, 2012, 19, 72-81.	1.6	113
17	Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve. American Journal of Transplantation, 2020, 20, 1765-1767.	2.6	98
18	Miniature swine as organ donors for man: Strategies for prevention of xenotransplantâ€associated infections. Xenotransplantation, 1994, 1, 47-57.	1.6	96

#	Article	IF	CITATIONS
19	Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppressionâ€: Clinical Infectious Diseases, 2021, 73, e1302-e1317.	2.9	95
20	Porcine Cytomegalovirus Infection Is Associated With Early Rejection of Kidney Grafts in a Pig to Baboon Xenotransplantation Model. Transplantation, 2014, 98, 411-418.	0.5	91
21	Porcine cytomegalovirus and coagulopathy in pig-to-primate xenotransplantation1. Transplantation, 2003, 75, 1841-1847.	0.5	88
22	Infectious disease risks in xenotransplantation. American Journal of Transplantation, 2018, 18, 1857-1864.	2.6	84
23	Donor-derived infection—the challenge for transplant safety. Nature Reviews Nephrology, 2014, 10, 663-672.	4.1	80
24	Posttransplantation lymphoproliferative disease in miniature swine after allogeneic hematopoietic cell transplantation: similarity to human PTLD and association with a porcine gammaherpesvirus. Blood, 2001, 97, 1467-1473.	0.6	76
25	Reduction of Consumptive Coagulopathy Using Porcine Cytomegalovirus-Free Cardiac Porcine Grafts in Pig-to-Primate Xenotransplantation. Transplantation, 2004, 78, 1449-1453.	0.5	75
26	Opportunistic InfectionsComing to the Limits of Immunosuppression?. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a015669-a015669.	2.9	75
27	Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. The Lancet Gastroenterology and Hepatology, 2019, 4, 771-780.	3.7	66
28	Donor-Derived Transmission of Candida auris During Lung Transplantation. Clinical Infectious Diseases, 2017, 65, 1040-1042.	2.9	64
29	Pharmacologic immunosuppressive therapy and extracorporeal immunoadsorption in the suppression of antiâ€i±Gal antibody in the baboon. Xenotransplantation, 1998, 5, 274-283.	1.6	62
30	Surfactant Protein-A Reduces Binding and Phagocytosis of <i>Pneumocystis carinii</i> by Human Alveolar Macrophages <i>In Vitro</i> . American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 834-843.	1.4	62
31	Activation of Porcine Cytomegalovirus, but Not Porcine Lymphotropic Herpesvirus, in Pigâ€ŧoâ€Baboon Xenotransplantation. Journal of Infectious Diseases, 2004, 189, 1628-1633.	1.9	60
32	Progress Toward Cardiac Xenotransplantation. Circulation, 2020, 142, 1389-1398.	1.6	60
33	Infectious Disease Transmission during Organ and Tissue Transplantation. Emerging Infectious Diseases, 2012, 18, e1-e1.	2.0	60
34	Infection in Renal Transplant Recipients. Seminars in Nephrology, 2007, 27, 445-461.	0.6	58
35	Regulation of Clinical Xenotransplantation—Time for a Reappraisal. Transplantation, 2017, 101, 1766-1769.	0.5	57
36	Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. Clinical Infectious Diseases, 2019, 69, 909-920.	2.9	57

#	Article	IF	CITATIONS
37	Reduced Efficacy of Ganciclovir Against Porcine and Baboon Cytomegalovirus in Pig-to-Baboon Xenotransplantation. American Journal of Transplantation, 2003, 3, 1057-1064.	2.6	53
38	Early weaning of piglets fails to exclude porcine lymphotropic herpesvirus. Xenotransplantation, 2005, 12, 59-62.	1.6	49
39	Central Nervous System Syndromes in Solid Organ Transplant Recipients. Clinical Infectious Diseases, 2014, 59, 1001-1011.	2.9	49
40	Genomic presence of recombinant porcine endogenous retrovirus in transmitting miniature swine. Virology Journal, 2006, 3, 91.	1.4	47
41	COVIDâ€19 in solid organ transplant recipients: Dynamics of disease progression and inflammatory markers in ICU and nonâ€ICU admitted patients. Transplant Infectious Disease, 2020, 22, e13407.	0.7	45
42	Infection and Xenotransplantation: Developing Strategies to Minimize Risk. Annals of the New York Academy of Sciences, 1998, 862, 52-66.	1.8	44
43	Quantitation of Porcine Cytomegalovirus in Pig Tissues by PCR. Journal of Clinical Microbiology, 2001, 39, 1155-1156.	1.8	44
44	Absence of Replication of Porcine Endogenous Retrovirus and Porcine Lymphotropic Herpesvirus Type 1 with Prolonged Pig Cell Microchimerism after Pig-to-Baboon Xenotransplantation. Journal of Virology, 2008, 82, 12441-12448.	1.5	42
45	Pneumocystis jiroveci. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 141-157.	0.8	40
46	First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—Chapter 5: recipient monitoring and response plan for preventing disease transmission. Xenotransplantation, 2016, 23, 53-59.	1.6	38
47	Infection in Xenotransplantation. Journal of Cardiac Surgery, 2001, 16, 363-373.	0.3	37
48	Prevention of infection in xenotransplantation: Designated pathogenâ€free swine in the safety equation. Xenotransplantation, 2020, 27, e12595.	1.6	37
49	The Immunocompromised Transplant Recipient and SARS-CoV-2 Infection. Journal of the American Society of Nephrology: JASN, 2020, 31, 1147-1149.	3.0	36
50	Failure of Lowâ€Dose Atovaquone Prophylaxis againstPneumocystis jiroveciInfection in Transplant Recipients. Clinical Infectious Diseases, 2004, 38, e76-e78.	2.9	34
51	Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. American Journal of Transplantation, 2020, 20, 1619-1628.	2.6	31
52	Posttransplant Lymphoproliferative Disease After Allogeneic Transplantation of the Spleen in Miniature Swine. Transplantation, 2004, 78, 286-291.	0.5	26
53	Characteristics and Outcomes of Latinx Patients With COVID-19 in Comparison With Other Ethnic and Racial Groups. Open Forum Infectious Diseases, 2020, 7, ofaa401.	0.4	26
54	Case 11-2008. New England Journal of Medicine, 2008, 358, 1604-1613.	13.9	23

#	Article	IF	CITATIONS
55	Donorâ€derived infections and infectious risk in xenotransplantation and allotransplantation. Xenotransplantation, 2018, 25, e12423.	1.6	23
56	Infection in xenotransplantation: opportunities and challenges. Current Opinion in Organ Transplantation, 2019, 24, 527-534.	0.8	22
57	Utilization of increased risk for transmission of infectious disease donor organs in solid organ transplantation: Retrospective analysis of disease transmission and safety. Transplant Infectious Disease, 2017, 19, e12791.	0.7	20
58	A consideration of potential donors with active infection - is this a way to expand the donor pool?. Transplant International, 1998, 11, 333-335.	0.8	19
59	Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. Blood, 2019, 134, 211-215.	0.6	18
60	The Risk of Infection in Xenotransplantation: Introduction. Annals of the New York Academy of Sciences, 1998, 862, 45-51.	1.8	17
61	Smallpox and Live-Virus Vaccination in Transplant Recipients. American Journal of Transplantation, 2003, 3, 786-793.	2.6	16
62	Absence of interaction between porcine endogenous retrovirus and porcine cytomegalovirus in pigâ€ŧoâ€baboon renal xenotransplantation in vivo. Xenotransplantation, 2018, 25, e12395.	1.6	11
63	Reply 2 to "Xenotransplantation—caution, but no moratorium― Nature Medicine, 1998, 4, 372-372.	15.2	9
64	Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation. New England Journal of Medicine, 2020, 383, 1168-1180.	13.9	9
65	Conversion to Full Donor Chimerism without Gvhd Using High-Dose DLI in Minimally Conditioned Miniature Swine Recipients of Haploidentical HCT Blood, 2008, 112, 2336-2336.	0.6	9
66	Discrepant serological assays for <i>Pneumococcus</i> in renal transplant recipients - a prospective study. Transplant International, 2017, 30, 689-694.	0.8	7
67	Early detection of SARS oVâ€2 and other infections in solid organ transplant recipients and household members using wearable devices. Transplant International, 2021, 34, 1019-1031.	0.8	6
68	A consideration of potential donors with active infection - is this a way to expand the donor pool?. Transplant International, 1998, 11, 333-335.	0.8	6
69	Donor Lymphocyte Infusion–Mediated Graft-versus-Host Responses in a Preclinical Swine Model of Haploidentical Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1953-1960.	2.0	5
70	Innovation in organ transplantation: A meeting report. American Journal of Transplantation, 2018, 18, 1875-1878.	2.6	5
71	Infection in Kidney Transplant Recipients. , 2019, , 517-538.		5
72	Cross-Reactive Antigens of the Rat and HumanPneumocystis carinii. Journal of Protozoology, 1989, 36, 66s-67s.	0.9	4

JAY A FISHMAN

#	Article	IF	CITATIONS
73	Editorial Commentary: Immune Reconstitution Syndrome: How Do We "Tolerate" Our Microbiome?. Clinical Infectious Diseases, 2015, 60, 45-47.	2.9	4
74	Mycobacterium tuberculosis in transplantation: Immunity sufficient to perpetuate disease?. American Journal of Transplantation, 2019, 19, 1262-1263.	2.6	4
75	Mentorship in academic medicine: Competitive advantage while reducing burnout?. Health Sciences Review, 2021, 1, 100004.	0.6	4
76	An Improved Rat Model to Study Efficacy of Drugs for Treatment or Prophylaxis <i>of Pneumocystis carinii</i> Pneumonia. Journal of Protozoology, 1989, 36, 77S-78S.	0.9	3
77	Screening of source animals and clinical monitoring for xenotransplantation. Xenotransplantation, 2007, 14, 349-352.	1.6	3
78	An Improved Rat Model to Study Efficacy of Drugs for Treatment or Prophylaxis ofPneumocystis cariniiPneumonia. Journal of Protozoology, 1989, 36, 77s-78s.	0.9	2
79	Xenotransplantation and Its Implications: Background Information for the Press. Annals of the New York Academy of Sciences, 1998, 862, 237-250.	1.8	2
80	Case 10-2004. New England Journal of Medicine, 2004, 350, 1339-1347.	13.9	2
81	Humoral immune responses against SARSâ€CoVâ€⊋ in transplantation: Actionable biomarker or misplaced trust?. American Journal of Transplantation, 2022, , .	2.6	1
82	Reply to Antinori et al. Clinical Infectious Diseases, 2014, 59, 1653-1654.	2.9	0
83	Changing Patterns of Respiratory Viral Infections in Transplant Recipients. , 0, , 69-84.		0
84	Commentary: The Advisory Committee on Immunization Practices' ethical principles for allocating initial supplies of COVIDâ€19 vaccine — United States, 2020. American Journal of Transplantation, 2021, 21,	2.6	0

initial supplies of COVIDâ€19 vaccine — United States, 2020. American Journal of Transplantation, 2021, 21, 419-419. 2.6 84